56P Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2020.08.034 ◽

2020 ◽

Vol 31 ◽

pp. S262-S263

Author(s):

J. Zhou ◽

J. Fan ◽

G. Shi ◽

X. Huang ◽

D. Wu ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Intrahepatic Cholangiocarcinoma ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Randomized, Open, Prospective, Phase II Clinical Trial of Doxorubicin (DOXO) vs. Trabectedin Plus Doxo in the First-Line Treatment of Patients (PTS) with Advanced Non-Operable and/or Metastatic Soft Tissue Sarcomas (STS): Geis-20 Study

Annals of Oncology ◽

10.1016/s0923-7534(20)34065-5 ◽

2012 ◽

Vol 23 ◽

pp. ix490 ◽

Author(s):

J. Martin Broto ◽

X. Garcia Del Muro ◽

A. Lopez-Pousa ◽

R. Las De Penas ◽

J. Maurel ◽

...

Keyword(s):

Clinical Trial ◽

Soft Tissue ◽

Phase Ii ◽

Soft Tissue Sarcomas ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

Prospective Phase ◽

First Line Treatment

Download Full-text

Chemotherapy with or without autologous cytokine-induced killer cell transfusion as the first-line treatment for stage IV gastrointestinal cancer: a phase II clinical trial

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-016-2127-2 ◽

2016 ◽

Vol 142 (6) ◽

pp. 1315-1323 ◽

Author(s):

Ying-Chun Xu ◽

Qi Xu ◽

Jun-Jian Li ◽

Xiao-Feng Gu ◽

Xiao-Lin Lin ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Gastrointestinal Cancer ◽

Killer Cell ◽

Stage Iv ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

1404P Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1513 ◽

2021 ◽

Vol 32 ◽

pp. S1058

Author(s):

J. Wang ◽

T. Wu ◽

Y-G. Hong ◽

S-X. Luo ◽

N. Li ◽

...

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

Cancer Communications ◽

10.1002/cac2.12119 ◽

2020 ◽

Vol 40 (12) ◽

pp. 711-720

Author(s):

Bo Zhang ◽

Ling Qi ◽

Xi Wang ◽

Jianping Xu ◽

Yun Liu ◽

...

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

1131 POSTER Addition of CPG 7909 to taxane/platinum regimen for first-line treatment of unresectable NSCLC improves objective response in phase II clinical trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81425-9 ◽

2005 ◽

Vol 3 (2) ◽

pp. 326-327 ◽

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Objective Response ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

Annals of Translational Medicine ◽

10.21037/atm-20-2990 ◽

2020 ◽

Vol 8 (17) ◽

pp. 1047-1047

Author(s):

Zhenyu Hou ◽

Keyun Zhu ◽

Xuejiao Yang ◽

Ping Chen ◽

Wei Zhang ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

A phase II clinical trial of ZD1839 (Iressa™) in combination with docetaxel as first-line treatment in patients with advanced breast cancer

Investigational New Drugs ◽

10.1007/s10637-007-9055-6 ◽

2007 ◽

Vol 25 (6) ◽

pp. 545-551 ◽

Author(s):

Sheri K. Dennison ◽

Samuel A. Jacobs ◽

John W. Wilson ◽

Janell Seeger ◽

Terrence P. Cescon ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Advanced Breast ◽

Line Treatment ◽

First Line Treatment

Download Full-text

424P Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial

Annals of Oncology ◽

10.1016/j.annonc.2021.08.945 ◽

2021 ◽

Vol 32 ◽

pp. S546-S547

Author(s):

Y. Jin ◽

Y. Han ◽

L. Zhang ◽

Y. Jin ◽

H. Sun

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line Treatment

Download Full-text

About the Recently Published Paper on JAMA Oncology “Radioembolization Plus Chemotherapy for First-Line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial”

CardioVascular and Interventional Radiology ◽

10.1007/s00270-020-02577-4 ◽

2020 ◽

Vol 43 (9) ◽

pp. 1418-1419

Author(s):

Irene Bargellini ◽

Caterina Vivaldi ◽

Laura Crocetti ◽

Gianluca Masi

Keyword(s):

Clinical Trial ◽

Intrahepatic Cholangiocarcinoma ◽

Locally Advanced ◽

Line Treatment ◽

Phase 2 ◽

Phase 2 Clinical Trial ◽

Published Paper ◽

First Line Treatment

Download Full-text

Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4565 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4565-4565 ◽

Author(s):

Ai-Ping Zhou ◽

Jianhui Ma ◽

Yuxian Bai ◽

Yan Song ◽

Hangzhong Li ◽

...

Keyword(s):

Clinical Trial ◽

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text